A RAF/MEK plus FAK inhibitor combination will be given an expedited review by the FDA as therapy for patients with recurrent low-grade serous ovarian cancer.
By Audrey Sternberg
The combination of the RAF/MEK inhibitor, VS-6766, plus the FAK inhibitor, defactinib, … Read more
By Jennifer Southall
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology… Read more
By Professor Ian Jacobs
I was motivated to improve the outcome for women with ovarian cancer by my experience as a junior doctor in London in 1985. But 36 years on, the results aren’t what we’d hoped.
My colleages’ and
… Read moreBy Pam Harrison
Results from a huge British trial that involved more than 200,000 women who were followed for a median of 16 years have turned out negative. Investigators found that annual screening for ovarian cancer with either multimodal screening … Read more
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
Luci Berardi had known for three months that something was wrong. As a yoga practitioner and instructor, she was very much in tune with her body, and the changes she was noticing were odd and disconcerting.
First there was the … Read more
For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
The research from UVA’s Jogender Tushir-Singh, PhD, explains why … Read more
Ovarian cancer is a serious gynecologic cancer and the fifth leading cause of cancer-related deaths among women in the United States.1 To minimize the risk of the coronavirus disease (COVID-19) transmission while … Read more
Ixabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more
Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.
By Charles Bankhead
Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.
Median progression-free survival (PFS) doubled … Read more
October of 2019, I had my initial tumor removal via an oophorectomy. My oncologist was extremely empathetic and insisted that all measures would be taken to preserve my fertility given my age. However, on November 13, 2019, three weeks following … Read more
By Chase Doyle
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the … Read more
By Chase Doyle
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT … Read more
Responses in 37% of patients with AVB-500, higher without prior bevacizumab.
By Charles Bankhead
More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more
Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due … Read more
Modest improvement in PFS with rucaparib but worse outcome for reversion mutation.
By Charles Bankhead
A PARP inhibitor slowed progression of recurrent, advanced BRCA-positive ovarian cancer as compared with standard chemotherapy, a randomized trial showed.
Treatment with rucaparib (Rubraca) … Read more
